Cargando…

IL-15 Is Overexpressed in γδ T Cells and Correlates with Disease Severity in Relapsing-Remitting Multiple Sclerosis

Interleukin 15 (IL-15) is known to be involved in the pathogenesis of multiple sclerosis (MS). An animal study revealed a distinct subset of IL-15-producing γδ T cells that correlate with disease severity. The aim of the current study was to test whether such a subset is also present in humans and i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zarobkiewicz, Michał K., Kowalska, Wioleta, Morawska, Izabela, Halczuk, Paweł, Rejdak, Konrad, Bojarska-Junak, Agnieszka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467081/ https://www.ncbi.nlm.nih.gov/pubmed/34575283 http://dx.doi.org/10.3390/jcm10184174

Ejemplares similares

PECAM-1 Is Down-Regulated in γδT Cells during Remission, but Up-Regulated in Relapse of Multiple Sclerosis
por: Zarobkiewicz, Michał K., et al.
Publicado: (2022)

Reduced Percentage of CD14(dim)CD16(+)SLAN(+) Monocytes Producing TNF and IL-12 as an Immunological Sign of CLL Progression
por: Kowalska, Wioleta, et al.
Publicado: (2022)

γδ T Lymphocytes in Asthma: a Complicated Picture
por: Zarobkiewicz, Michał K., et al.
Publicado: (2021)

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)
por: Zarobkiewicz, Michał K., et al.
Publicado: (2022)

High M-MDSC Percentage as a Negative Prognostic Factor in Chronic Lymphocytic Leukaemia
por: Zarobkiewicz, Michał, et al.
Publicado: (2020)

NKT and NKT-like Cells in Autoimmune Neuroinflammatory Diseases—Multiple Sclerosis, Myasthenia Gravis and Guillain-Barre Syndrome
por: Zarobkiewicz, Michał K., et al.
Publicado: (2021)

Prognostic Potential of Galectin-9 mRNA Expression in Chronic Lymphocytic Leukemia
por: Bojarska-Junak, Agnieszka, et al.
Publicado: (2023)

Pro- vs. Anti-Inflammatory Features of Monocyte Subsets in Glioma Patients
por: Lehman, Natalia, et al.
Publicado: (2023)

Tumor infiltrating lymphocytes and radiological picture of the tumor
por: Frankowska, Karolina, et al.
Publicado: (2023)

Effect of immunostimulation with bacterial lysate on the clinical course of allergic rhinitis and the level of γδT, iNKT and cytotoxic T cells in children sensitized to grass pollen allergens: A randomized controlled trial
por: Janeczek, Kamil, et al.
Publicado: (2023)

Prognostic Value of the miR-17~92 Cluster in Chronic Lymphocytic Leukemia
por: Chocholska, Sylwia, et al.
Publicado: (2023)

Prognostic Value of Tie2-Expressing Monocytes in Chronic Lymphocytic Leukemia Patients
por: Woś, Justyna, et al.
Publicado: (2021)

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
por: Kappos, Ludwig, et al.
Publicado: (2015)

Neutral endopeptidase (NEP) is differentially involved in biological activities and cell signaling of colon cancer cell lines derived from various stages of tumor development
por: Mizerska-Kowalska, Magdalena, et al.
Publicado: (2016)

Sexual dysfunction in female patients with relapsing‐remitting multiple sclerosis
por: Bartnik, Pawel, et al.
Publicado: (2017)

A Modified Method of Insulin Producing Cells' Generation from Bone Marrow-Derived Mesenchymal Stem Cells
por: Czubak, Paweł, et al.
Publicado: (2014)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
por: Jamroz-Wiśniewska, Anna, et al.
Publicado: (2021)

Skeletonized mean diffusivity and neuropsychological performance in relapsing‐remitting multiple sclerosis
por: Chylińska, Magdalena, et al.
Publicado: (2022)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

Longitudinal changes in the expression of IL-33 and IL-33 regulated genes in relapsing remitting MS
por: Sriram, Subramaniam, et al.
Publicado: (2018)

Decrease in Lipid Droplets in Adrenal Cortex of Male Wistar Rats after Chronic Exposure to Energy Drinks
por: Zarobkiewicz, Michał K., et al.
Publicado: (2018)

Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity
por: Hus, Iwona, et al.
Publicado: (2013)

A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies
por: Waldowska, Małgorzata, et al.
Publicado: (2017)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

Upper Respiratory Tract Colonization by Gram-Negative Rods in Patients with Chronic Lymphocytic Leukemia: Analysis of Risk Factors
por: Korona-Glowniak, Izabela, et al.
Publicado: (2012)

A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis
por: Fox, Robert J., et al.
Publicado: (2022)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
por: Romme Christensen, Jeppe, et al.
Publicado: (2012)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi, Alessandra, et al.
Publicado: (2013)

Defective structural RNA processing in relapsing-remitting multiple sclerosis
por: Spurlock, Charles F, et al.
Publicado: (2015)

Thalamic–hippocampal–prefrontal disruption in relapsing–remitting multiple sclerosis
por: Kern, Kyle C., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hg7pu79k4jao6ak5jgaj58jehv